Results 51 to 60 of about 86,084 (265)

OSMANLILAR DÖNEMİNDE YETİMLERLE İLGİLİ FARKLI BİR UYGULAMA: KÜLHANBEYLİĞİ KURUMU

İstem, 2007
Osmanlılar döneminde yetim çocuklarla ilgili olarak, genelde kaynağını İslâm’dan ve Türk kültüründen alan, çok olumlu uygulamalar gerçekleştirilmiştir. Fakat bu genel durumun istisnaları ve olumsuz gelişmeler de söz konusudur. Bu makalemizde biz, işte bu
Nesimi Yazıcı
doaj  

Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review

Clinical Epidemiology, 2020
Kevin Yan,1,2 Kamal Desai,1 Lakshmi Gullapalli,1 Eric Druyts,1 Chakrapani Balijepalli1 1Pharmalytics Group, Vancouver, British Columbia, Canada; 2Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaCorrespondence ...
Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C   +4 more
doaj  

Legal and ethical considerations around the use of existing illustrations to generate new illustrations in the anatomical sciences

Anatomical Sciences Education, Volume 18, Issue 3, Page 289-300, March 2025.
Abstract It is likely existing anatomical illustrations are often used as the basis for new illustrative works, given not all illustrators have access to human tissues, bodies, or prosections on which to base their illustrations. Potential issues arise with this practice in the realms of copyright infringement and plagiarism when authors are seeking to
Jon Cornwall, Richard White, Patrick Pennefather, Sabine Hildebrandt, Jill Gregory, Heather F. Smith, Jason Organ, Claudia Krebs   +7 more
wiley   +1 more source

The valued focus of a widow and an orphan statuses and scale of protection in the Old and New Testament tradition

Cхід, 2018
The article is devoted to a problem of a widow's place, status, scale of protection and vulnerability consideration due to the biblical tradition. Moreover, it discovers a problem of widows' and orphans' solitude and their incorporation into social life.
Svitlana Khrypko
doaj   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

From cramming to binge‐watching: Integrating documentary‐based assessment into a pharmacology and toxicology curriculum—a qualitative study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi, Heleen van der Sijs, Floor van Rosse   +2 more
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source